Crystalline forms of a hepatitis b antiviral agent

A form, crystal technology, applied in the field of crystal form of hepatitis B antiviral agent, can solve the problems of reducing purity, instability and the like

Inactive Publication Date: 2018-08-21
NOVIRA THERAPEUTICS
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, certain crystalline solid compounds can overcome disadvantages of other solid forms of the compound, such as instability and / or reduced purity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline forms of a hepatitis b antiviral agent
  • Crystalline forms of a hepatitis b antiviral agent
  • Crystalline forms of a hepatitis b antiviral agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0235] Embodiment 1: the synthesis of compound (1)

[0236] I. Published Synthesis :

[0237] The following syntheses are disclosed in PCT Publication WO / 2013 / 096744, which is hereby incorporated by reference in its entirety.

[0238] Reaction scheme :

[0239]

[0240]

[0241] Step 1: Preparation of compound 2

[0242] Compound 1a (10.0 g, 42.0 mmol) was dissolved in SOCl 2 (60 mL) was heated to reflux overnight. The mixture was concentrated in vacuo. The residue was dissolved with toluene (30 mL) and concentrated in vacuo to give the crude product which was used directly in the next step.

[0243] Step 2: Preparation of compound 3

[0244]To a boiling solution of crude compound 2 (42 mmol) in toluene (100 mL) was slowly added a suspension of aniline (6.17 g, 42 mmol) in toluene (40 mL) and refluxed for 2 hours. The mixture was concentrated in vacuo to obtain a solid which was used directly in the next step.

[0245] Step 3: Preparation of compound ...

Embodiment 2

[0269] Example 2: Anhydrous Form I of Compound (1)

[0270] I. Process for Forming Anhydrous Form I of Compound (1) :

[0271] The following procedure was developed for the preparation of Form I of compound (1).

[0272] Acetone (5.3V) was added to compound (1) at 45°C. Water was then added, and the solution was filtered at 45°C to remove mechanical impurities. Then, the solution was cooled to 20°C and poured into water (2.5V) as quickly as possible. Agglomeration occurs during this process, ie crystallization in the form of acetone. The solution was further cooled to 10°C, thereby consuming supersaturation. Then, it was slurried with a mixture of acetone and water (50 / 50) at 10° C. at 3 V, and then washed with a solution of the mixture. Filtration and drying under vacuum at about 50°C yields Form III of compound (1).

[0273] A slurry was formed from the resulting Form III of compound (1) mixed with methyl tert-butyl ether (MTBE) at 25°C for at least 4 hours. This ...

Embodiment 3

[0292] Example 3: Formation and Characterization of Anhydrous Crystal Form of Compound (1) (Form XVI)

[0293] I. Process for Forming Form XVI of Compound (1) :

[0294]Acetone (7V) was added to compound (1) at 45°C. Water (3V) was added, and the solution was filtered to remove mechanical impurities. The solution was then cooled to 20° C., and the solution was seeded with 0.7% of Form III of compound (1 ) to form Form III. Additional water (4V) was added to achieve a 50 / 50 ratio of acetone to water. The solution was then cooled to 10°C over 20 minutes to consume supersaturation. Then, it was slurried with a mixture of acetone and water (50 / 50) at 10° C. at 4 V, and then washed with a solution of the mixture. Filtration and drying at about 50°C under nitrogen saturated with acetone yielded Form III of compound (1). Further filtration and drying under nitrogen at about 50°C yields "dry" Form III of compound (1).

[0295] A slurry was formed from the resulting dry form ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

This disclosure provides crystalline forms of a hepatitis B antiviral agent, and methods of making and using these forms.

Description

[0001] Related Patent Applications [0002] This patent application claims priority to US Provisional Patent Application 62 / 234,124, filed September 29, 2015, the contents of which are incorporated herein in their entirety. technical field [0003] The present disclosure relates to a crystalline form of 4-fluoro-3-((4-hydroxypiperidin-1-yl)sulfonyl)-N-(3,4,5-trifluorophenyl)benzamide, or a hydrate thereof or solvates, and methods of making and using these forms. Background technique [0004] The solid state of the compound may be important when the compound is used for pharmaceutical purposes. The physical properties of a compound can change from one solid form to another, which can affect the stability of the form for pharmaceutical use. For example, a particular crystalline solid compound may overcome disadvantages of other solid forms of the compound, such as instability and / or reduced purity. [0005] Provided herein is the solid crystalline form of 4-fluoro-3-((4-hy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): C07D211/96A61K31/45A61P31/12
CPCA61P31/12A61P31/20C07D211/96C07B2200/13
InventorG.D.哈特曼
OwnerNOVIRA THERAPEUTICS